Understanding the Suboxone Lawsuit

Why is there a lawsuit against Suboxone film?

The lawsuits against the manufacturers of Suboxone film revolve around serious allegations of failing to warn patients about the significant risk of dental complications and engaging in deceptive marketing practices.

• Failure to Warn: Companies like Indivior, Reckitt Benckiser, and more manufacturers are accused of not providing adequate warnings about the severe dental problems associated with their medications. Many patients were unaware of the potential for significant oral health issues, only discovering the problems after extensive use.
• Deceptive Marketing: These companies allegedly marketed their opioid medications as safe and effective treatments without properly disclosing the risk of dental complications, misleading both patients and healthcare providers.
• Formulation Risks: The specific formulations of these medications, especially Suboxone’s film version, have been implicated in contributing to dental issues like tooth decay and other serious problems.

Suboxone Film Dental Health Side Effects

After six months of use, Suboxone film unleashes a cascade of dental challenges that aren't just health issues—they're deeply personal battles that affect daily life.

• Cavities
• Tooth Loss
• Tooth Fractures
• Tooth Decay
• Tongue Injuries
• Gum Injuries

Suboxone film's formula, with its acidic nature primarily from buprenorphine, hastens the breakdown of tooth enamel. This acidity strips away the protective layers of enamel, making teeth susceptible to decay and fractures. Over time, these serious dental issues intensify, adding emotional and physical strain to those affected.

Suboxone Mass Tort Milestones

2007-2013: Early Warnings

Reports surfaced in 2007 linking Suboxone, particularly its film formulation, to severe dental issues. These concerns gained traction with compelling studies from Harvard Medical School in 2012 and 2013, documenting cases where patients suffered significant dental decay and erosion linked to prolonged Suboxone use.

December 2016: FDA Issues Strong Warnings

The FDA issued warnings about serious risks associated with long-term use of opioid pain medications, including Suboxone, highlighting concerns about addiction, overdose, and death.

June 2018: FDA Approval of Generic Suboxone Film

The FDA approved the first generic versions of Suboxone sublingual film, potentially increasing access to treatment while influencing ongoing legal and regulatory actions.

2019: Legal & Criminal Settlements

Indivior settled with the U.S. Department of Justice for $600 million over allegations of misleading marketing practices for Suboxone. Reckitt Benckiser, Indivior's former parent company, settled criminal charges totaling $1.4 billion related to Suboxone's marketing, addressing claims of deceptive tactics and monopoly practices.

2022: FDA Official Warnings

The FDA officially recognized the potential for medications like Suboxone film, which dissolves in the mouth, to cause significant dental problems, resulting in updated warnings on the drug's labeling and patient information.

April-October 2023: FTC Fights for Consumers

The FTC championed consumers early in the year by securing settlements for those who missed initial payouts and tackling anti-competitive practices by Indivior and Reckitt Benckiser, ensuring fair market competition.

September 2023: First Dental Lawsuits Filed

September saw the first wave of lawsuits against Indivior and Reckitt Benckiser for Suboxone’s severe dental damage. This marked the start of a major legal offensive, seeking justice for many affected users.

October 2023: Legal Intensity & Consolidation

Legal action surged as new lawsuits were filed against Indivior in federal courts, amplifying the urgency of addressing Suboxone’s alleged dental health implications.

January-February 2024: Hearing for Unity

The Judicial Panel on Multidistrict Litigation consolidated multiple Suboxone dental complication cases in Ohio, aiming to expedite legal proceedings and ensure consistent rulings.

May 2024: Strategizing for Justice

Attorneys are working to set deadlines for addressing key legal issues in the Suboxone film lawsuit. This careful planning is crucial for a fair and thorough battle ahead.

June 2024: Denial of Phased Discovery in Suboxone Lawsuits

A federal judge denied Suboxone manufacturers' request for phased discovery, citing concerns about hindering the search for scientific truth and impeding overall progress in the litigation. The Suboxone lawsuits will now advance with standard discovery procedures in preparation for early trial dates, crucial for assessing potential jury responses and influencing future settlement negotiations.

The collective pursuit of justice and compensation remains active and ongoing.

Moving Forward Together

In the Suboxone mass tort collective, you are not just another case—you are part of a powerful movement to hold corporations accountable for their actions. Your voice, along with those of countless others, amplifies the demand for justice against the manufacturers who failed to warn about the severe dental complications linked to Suboxone film.

We understand the profound impact these issues have had on your life. Our dedicated legal team is diving deep into the evidence, uncovering critical details, and preparing to confront these corporations. We are not just your law film; we are your support advocates guiding you every step of the way.

If you have any questions, please do not hesitate to reach out. We’re always here for you. Together, we will fight for the accountability, justice, and fair compensation that you deserve.